Provided by Tiger Fintech (Singapore) Pte. Ltd.

DOGWOOD THERAPEUTICS INC

4.82
+0.05001.05%
Post-market: 4.820.00000.00%16:22 EDT
Volume:9.85K
Turnover:47.17K
Market Cap:9.21M
PE:-0.24
High:4.90
Open:4.90
Low:4.75
Close:4.77
Loading ...

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

GlobeNewswire
·
18 Mar

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…

Zacks Small Cap Research
·
18 Mar

Sector Update: Health Care Stocks Softer Thursday Afternoon

MT Newswires Live
·
14 Mar

Maxim Group Remains a Buy on Dogwood Therapeutics (DWTX)

TIPRANKS
·
14 Mar

Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge

MT Newswires Live
·
13 Mar

Dogwood Therapeutics Inc: Proceeds From Financing, When Added to Existing Cash, Fund Operations Through Q1 2026

THOMSON REUTERS
·
13 Mar

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
13 Mar

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
13 Mar

DWTX Stock trading resumes

TIPRANKS
·
10 Mar

DWTX Stock trading halted, volatility trading pause

TIPRANKS
·
10 Mar

Dogwood Therapeutics Inc expected to post a loss of $1.41 a share - Earnings Preview

Reuters
·
24 Feb

DWTX Stock trading resumes

TIPRANKS
·
12 Feb

DWTX Stock trading halted, volatility trading pause

TIPRANKS
·
12 Feb

4 Stocks to Buy on Trump’s Turbocharged News Cycle

InvestorPlace
·
10 Feb

DWTX Stock trading resumes

TIPRANKS
·
27 Jan

DWTX Stock trading halted, volatility trading pause

TIPRANKS
·
27 Jan

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

TIPRANKS
·
21 Jan

Dogwood Therapeutics Announces Patient Dosing in Phase 2B Trial Evaluating Halneuron® in Patients With Chemotherapy Induced Neuropathy (Cinp) to Commence First Quarter of 2025

THOMSON REUTERS
·
21 Jan

Dogwood Therapeutics Inc - Interim Data From Phase 2 Cinp Study Expected in 2H 2025

THOMSON REUTERS
·
21 Jan